The mitochondria-targeting peptide elamipretide diminishes circulating HtrA2 in ST-segment elevation myocardial infarction

European Heart Journal: Acute Cardiovascular Care

Volumn 8, Issue 8, 2019, Pages 695-702

  Hortmann, Marcus ^a   Robinson, Samuel ^a,b   Mohr, Moritz ^a   Mauler, Maximillian ^a   Stallmann, Daniela ^a   Reinöhl, Jochen ^a   Duerschmied, Daniel ^a   Peter, Karlheinz ^b,c   Carr, James ^d   Gibson, C Michael ^e   Bode, Christoph ^a   Ahrens, Ingo ^a,f  

^a UNIVERSITY OF FREIBURG   (Germany)

^b MONASH UNIVERSITY   (Australia)

^c BAKER IDI HEART AND DIABETES INSTITUTE   (Australia)

^d BIOTHERAPEUTICS INC   (United States)

^e HARVARD MEDICAL SCHOOL   (United States)

^f UNIVERSITY OF COLOGNE   (Germany)

Author keywords

apoptosis; Elamipretide; HtrA2; ischaemia reperfusion injury; mitochondria; ST segment elevation myocardial infarction

Indexed keywords

ACETYLSALICYLIC ACID; AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; CLOPIDOGREL; CREATINE KINASE; CREATININE; CYTOCHROME C; ELAMIPRETIDE; LACTATE DEHYDROGENASE; PRASUGREL; SERINE PROTEINASE OMI; TICAGRELOR;

ADULT; AGED; ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTERY OCCLUSION; ARTICLE; BLOOD SAMPLING; CARDIAC MUSCLE CELL; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ANGIOGRAPHY; ECHOCARDIOGRAPHY; ENZYME LINKED IMMUNOSORBENT ASSAY; GRACE RISK SCORE; HUMAN; LEFT ANTERIOR DESCENDING CORONARY ARTERY; MIDDLE AGED; MITOCHONDRION; MOUSE; MYOCARDIAL ISCHEMIA REPERFUSION INJURY; NONHUMAN; PERCUTANEOUS CORONARY INTERVENTION; PHASE 2 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROTEIN TARGETING; ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; THORACOTOMY;

EID: 85164546610     PISSN: 20488726     EISSN: 20488734     Source Type: Journal    
DOI: 10.1177/2048872617710789     Document Type: Article

References (20)

1. Yellon DM, Hausenloy DJ. Myocardial reperfusion injury. N Engl J Med 2007; 357: 1121–1135.
2. Hashmi S, Al-Salam S. Acute myocardial infarction and myocardial ischemia–reperfusion injury: a comparison. Int J Clin Exp Pathol 2015; 8: 8786–8796.
3. Gustafsson AB, Gottlieb RA. Heart mitochondria: gates of life and death. Cardiovasc Res 2008; 77: 334–343.
4. Webster KA. Mitochondrial membrane permeabilization and cell death during myocardial infarction: roles of calcium and reactive oxygen species. Future Cardiol 2012; 8: 863–884.
5. Bhuiyan MS, Fukunaga K. Activation of HtrA2, a mitochondrial serine protease mediates apoptosis: current knowledge on HtrA2 mediated myocardial ischemia/reperfusion injury. Cardiovasc Ther 2008; 26: 224–232.
6. Liu HR, Gao E, Hu A, et al. Role of Omi/HtrA2 in apoptotic cell death after myocardial ischemia and reperfusion. Circulation 2005; 111: 90–96.
7. Wang K, Zhang J, Liu J, et al. Variations in the protein level of Omi/HtrA2 in the heart of aged rats may contribute to the increased susceptibility of cardiomyocytes to ischemia/reperfusion injury and cell death: Omi/HtrA2 and aged heart injury. Age (Dordr) 2013; 35: 733746.
8. Liu ZB, Fu XH, Wei G, et al. Cytochrome c release in acute myocardial infarction predicts poor prognosis and myocardial reperfusion on contrast-enhanced magnetic resonance imaging. Coron Artery Dis 2014; 25: 66–72.
9. Marenzi G, Giorgio M, Trinei M, et al. Circulating cytochrome c as potential biomarker of impaired reperfusion in ST-segment elevation acute myocardial infarction. Am J Cardiol 2010; 106: 1443–1449.
10. Jemmerson R, LaPlante B, Treeful A. Release of intact, monomeric cytochrome c from apoptotic and necrotic cells. Cell Death Differ 2002; 9: 538–548.
11. Birk AV, Liu S, Soong Y, et al. The mitochondrial-targeted compound SS-31 re-energizes ischemic mitochondria by interacting with cardiolipin. J Am Soc Nephrol 2013; 24: 1250–1261.
12. Dai W, Shi J, Gupta RC, et al. Bendavia, a mitochondria-targeting peptide, improves postinfarction cardiac function, prevents adverse left ventricular remodeling, and restores mitochondria-related gene expression in rats. J Cardiovasc Pharmacol 2014; 64: 543–553.
13. Kloner RA, Hale SL, Dai W, et al. Reduction of ischemia/reperfusion injury with bendavia, a mitochondria-targeting cytoprotective peptide. J Am Heart Asso. 2012; 1: e001644.
14. Gibson CM, Giugliano RP, Kloner RA, et al. EMBRACE STEMI study: a Phase 2a trial to evaluate the safety, tolerability, and efficacy of intravenous MTP-131 on reperfusion injury in patients undergoing primary percutaneous coronary intervention. Eur Heart J 2016; 37: 1296–1303.
15. Steg PG, James SK, Atar D, et al. ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation. Eur Heart J 2012; 33: 2569–2619.
16. Granger CB, Goldberg RJ, Dabbous O, et al. Predictors of hospital mortality in the global registry of acute coronary events. Arch Intern Med 2003; 163: 2345–2353.
17. Bhuiyan MS, Fukunaga K. Inhibition of HtrA2/Omi ameliorates heart dysfunction following ischemia/reperfusion injury in rat heart in vivo. Eur J Pharmacol 2007; 557: 168–177.
18. Wang K, Yuan Y, Liu X, et al. Cardiac specific overexpression of mitochondrial Omi/HtrA2 induces myocardial apoptosis and cardiac dysfunction. Sci Rep 2016; 6: 37927.
19. Piot C, Croisille P, Staat P, et al. Effect of cyclosporine on reperfusion injury in acute myocardial infarction. N Engl J Med 2008; 359: 473–481.
20. Lonborg JT. Targeting reperfusion injury in the era of primary percutaneous coronary intervention: hope or hype? Heart 2015; 101: 1612–1618.